These findings underscore the potential of 64Cu-CD4-Nb1 PET imaging to provide mechanistic insights into CD4-mediated immune responses and resistance, paving the way for its use in guiding combinatorial immunotherapy strategies in patients with cancer. Here, CD4 is linked to cancer.